JP2022506062A5 - - Google Patents
Info
- Publication number
- JP2022506062A5 JP2022506062A5 JP2021523218A JP2021523218A JP2022506062A5 JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5 JP 2021523218 A JP2021523218 A JP 2021523218A JP 2021523218 A JP2021523218 A JP 2021523218A JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5
- Authority
- JP
- Japan
- Prior art keywords
- solid formulation
- formulation according
- solid
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752685P | 2018-10-30 | 2018-10-30 | |
| US62/752,685 | 2018-10-30 | ||
| PCT/US2019/057725 WO2020092100A1 (en) | 2018-10-30 | 2019-10-23 | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506062A JP2022506062A (ja) | 2022-01-17 |
| JP2022506062A5 true JP2022506062A5 (https=) | 2022-10-20 |
| JP7425794B2 JP7425794B2 (ja) | 2024-01-31 |
Family
ID=70464349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523218A Active JP7425794B2 (ja) | 2018-10-30 | 2019-10-23 | 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12358870B2 (https=) |
| EP (1) | EP3873443A4 (https=) |
| JP (1) | JP7425794B2 (https=) |
| KR (1) | KR20210091191A (https=) |
| CN (1) | CN112955130A (https=) |
| MX (1) | MX418110B (https=) |
| MY (1) | MY209101A (https=) |
| SG (1) | SG11202104208RA (https=) |
| WO (1) | WO2020092100A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| WO2021255159A1 (en) * | 2020-06-19 | 2021-12-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulation comprising daprodustat |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US11827614B2 (en) | 2021-05-21 | 2023-11-28 | Merck Sharp & Dohme Llc | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates |
| US12145901B1 (en) | 2021-09-17 | 2024-11-19 | Arcus Biosciences, Inc. | Process for preparing tetralin compounds |
| AU2023407370A1 (en) * | 2022-12-22 | 2025-07-03 | Cogent Biosciences, Inc. | Bezuclastinib formulations |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| KR102824931B1 (ko) * | 2023-10-17 | 2025-07-08 | 주식회사 참인티그레이션 | 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법 |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| EP1223952B1 (en) | 1999-10-07 | 2008-04-16 | Carlos Estuardo Aguilar-Cordova | Methods for treatment of solid tumors and metastasis by gene therapy |
| US7115265B1 (en) | 2001-05-14 | 2006-10-03 | Duke University | Four genetic tumor markers specific for human glioblastoma |
| PE20091041A1 (es) * | 2007-10-19 | 2009-08-22 | Abbott Gmbh & Co Kg | Producto de dispersion solida que contiene un compuesto a base de n-aril urea |
| US8691866B2 (en) * | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| WO2015009566A1 (en) * | 2013-07-19 | 2015-01-22 | Siga Technologies, Inc. | Amorphous tecovirimat preparation |
| PL3417851T3 (pl) | 2013-09-09 | 2020-12-14 | Peloton Therapeutics, Inc. | Etery arylowe i ich zastosowanie |
| EP3089736B1 (en) | 2013-12-31 | 2025-07-23 | Ascendia Pharmaceuticals, LLC | Pharmaceutical compositions for poorly water-soluble compounds |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
-
2019
- 2019-10-23 CN CN201980071770.6A patent/CN112955130A/zh active Pending
- 2019-10-23 MX MX2021005038A patent/MX418110B/es unknown
- 2019-10-23 EP EP19880015.3A patent/EP3873443A4/en active Pending
- 2019-10-23 WO PCT/US2019/057725 patent/WO2020092100A1/en not_active Ceased
- 2019-10-23 KR KR1020217016289A patent/KR20210091191A/ko active Pending
- 2019-10-23 MY MYPI2021002202A patent/MY209101A/en unknown
- 2019-10-23 US US17/286,581 patent/US12358870B2/en active Active
- 2019-10-23 JP JP2021523218A patent/JP7425794B2/ja active Active
- 2019-10-23 SG SG11202104208RA patent/SG11202104208RA/en unknown
-
2025
- 2025-06-30 US US19/254,916 patent/US20250326711A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506062A5 (https=) | ||
| Berl et al. | Oral tolvaptan is safe and effective in chronic hyponatremia | |
| Cook et al. | Development of GnRH antagonists for prostate cancer: new approaches to treatment | |
| US9486445B2 (en) | Combination therapy for proliferative disorders | |
| JP2020536884A5 (https=) | ||
| KR102319078B1 (ko) | 궤양성 대장염의 치료용 의약 조성물 | |
| JP2019516711A5 (https=) | ||
| JP2005525345A5 (https=) | ||
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2020514292A5 (https=) | ||
| JP2019514965A5 (https=) | ||
| JP2021535147A5 (https=) | ||
| JP2024502446A5 (https=) | ||
| JP2006518731A5 (https=) | ||
| IL292770A (en) | Formulations and dosages of polyethylene glycol-modified oricase | |
| EA032067B1 (ru) | Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита | |
| US11083722B2 (en) | Combination therapies for the treatment of breast cancer | |
| JP2020523317A5 (https=) | ||
| JP2018517759A5 (https=) | ||
| US20210393630A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| JP2021503448A5 (https=) | ||
| JP2014503589A5 (https=) | ||
| JP2024520307A5 (https=) | ||
| US20250268863A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| Shumar et al. | Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide |